Pharma giant Eli Lilly announced Monday that its gene-editing therapy can reduce LDL (“bad”) cholesterol by up to 62% with a single infusion. Not only was the experimental treatment successful, but ...
An experimental gene-editing therapy that aims to lower bad cholesterol for the long-term after a single infusion is off to a positive start in an early clinical trial. Researchers running a Phase I ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results